• Company
• Dt&CRO signs MOU with U.S. company Radyus Research
• by Nho, Byung Chul Mar 27, 2024 06:04am

• Policy
• Ruling party will focus on fostering Korea's pharma industry
• by Lee, Jeong-Hwan Mar 27, 2024 06:04am

• Policy
• 'Trajenta-duo' generics as SR tablets…55 approved items
• by Lee, Hye-Kyung Mar 27, 2024 06:04am

• Company
• No news on Phesgo's reimb progress for 7 months
• by Eo, Yun-Ho Mar 27, 2024 06:04am

• Company
• Adtralza reimb drives biologics competition in atopy market
• by Eo, Yun-Ho Mar 26, 2024 06:30am

• Company
• Sam Chun Dang Pharm introduces Eylea biosimilar to Europe
• by Nho, Byung Chul Mar 26, 2024 06:30am

• Policy
• MFDS reviews enacting a separate and special law for drugs
• by Lee, Hye-Kyung Mar 26, 2024 06:30am

• Company
• Takeda’s colorectal cancer drug 'Fruzaqla' nears KOR entry
• by Eo, Yun-Ho Mar 26, 2024 06:30am

• Policy
• Daewoong joins in competition in the Forxiga generic market
• by Lee, Tak-Sun Mar 26, 2024 06:30am

• Policy
• Pfizer tops global mkt…Samsung Biologics tops Korean mkt
• by Lee, Hye-Kyung Mar 26, 2024 06:30am